<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413153</url>
  </required_header>
  <id_info>
    <org_study_id>2005-P-002239</org_study_id>
    <nct_id>NCT00413153</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Switching Kaletra to Boosted Reyataz</brief_title>
  <official_title>Metabolic Effects of Switching Kaletra to Boosted Reyataz</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of switching from Kaletra to Boosted Reyataz on glucose, lipids and fat
      in HIV-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine tissue specific glucose trafficking in
      patients before and after switching from a regimen containing Lopinavir/ritonavir (LPV/r) to
      one containing atazanavir/ritonavir (ATV/r). Secondary outcome measures of interest will
      include insulin sensitivity determined by clamp testing, and lipid metabolism and hepatic
      glucose production assessed using stable isotope techniques. We hypothesize that switching
      protease inhibitor (PI) to ATV/r from LPV/r will result in direct increases in glucose uptake
      in muscle and visceral adipose tissue in association with improvements in overall whole body
      insulin sensitivity compared to remaining on LPV/r. We will complete a prospective randomized
      trial of Human Immunodeficiency Virus (HIV) infected patients who have been on a stable
      antiretroviral (ARV) regimen containing LPV/r for at least 6 months and who will be
      randomized to either switch to a regimen containing ATV/r or remain on LPV/r for 6 months.
      Each subject will complete Positron Emission Tomography (PET) 18-fluorodeoxyglucose (FDG)
      imaging during a hyperinsulinemic clamp study at baseline and 6 months after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Trafficking</measure>
    <time_frame>6 months</time_frame>
    <description>6 month mean and standard deviation for glucose uptake into anterior thigh muscle as measured by FDG/PET scanning during euglycemic hyperinsulinemic clamp. During the hyperinsulinemic conditions of the clamp, glucose and 18-FDG [labeled glucose] are taken up by muscle. The quantity of 18-FDG taken up is measured by the PET scan. Although there are no well-accepted norms for this measurement, a higher value indicates that more glucose is being taken up by (or &quot;trafficked to&quot;) muscle. Increased uptake of glucose indicates increased muscle insulin sensitivity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>6 month mean and standard deviation for insulin-stimulated glucose uptake (M) per unit insulin at 120 minutes as measured by euglycemic hyperinsulinemic clamp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>6 months</time_frame>
    <description>6 month mean and standard deviation for fasting glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Metabolism - Serum Triglyceride</measure>
    <time_frame>6 months</time_frame>
    <description>6 month mean and standard deviation for serum triglyceride.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition - Visceral Adipose Tissue</measure>
    <time_frame>6 months</time_frame>
    <description>6 month mean and standard deviation for visceral adipose tissue (VAT) as measured by single slice computed tomography (CT) scan at the L4 pedicle (pedicle of 4th lumbar vertebra).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Parameters -- CD4 Count</measure>
    <time_frame>6 months</time_frame>
    <description>6 month mean and standard deviation for CD4+ count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Enzymes -- Aspartate Aminotransferase (AST)</measure>
    <time_frame>6 months</time_frame>
    <description>6 month mean and standard deviation for AST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Enzymes -- Alanine Aminotransferase (ALT)</measure>
    <time_frame>6 months</time_frame>
    <description>6 month mean and standard deviation for ALT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin</measure>
    <time_frame>6 months</time_frame>
    <description>6 month mean and standard deviation for total bilirubin.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kaletra (pre-study dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir/ritonavir</intervention_name>
    <description>atazanavir 300mg + ritonavir 100mg once daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Boosted Reyataz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir</intervention_name>
    <description>patient remains on their pre-study dose of lopinavir/ritonavir</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Kaletra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Previously diagnosed HIV infection

          2. Age between 18-65 years

          3. Stable antiviral regimen containing at least 2 nucleoside reverse transcriptase
             inhibitors (NRTI's) and LPV/r for Â³ 6 mos

          4. CD4 count &gt; 400 cell/mm3

          5. Metabolic complication as indicated by one or more of hyperinsulinemia (fasting
             insulin &gt;= 15 mIU/ml), hypercholesteremia (fasting total cholesterol &gt;= 200 mg/dL),
             hypertriglyceridemia (fasting triglycerides &gt;= 150 mg/dL), or treatment with a lipid
             lowering medication.

        Exclusion Criteria:

          1. Hemoglobin &lt; 11.0 g/dL

          2. History of Diabetes Mellitus

          3. Currently on medication for Diabetes

          4. Therapy with glucocorticoid, growth hormone or other anabolic agents currently or
             within the past 3 months

          5. Current substance abuse, including alcohol, cocaine and/or heroin

          6. Any contraindication to ATV/r or known allergy to ATV

          7. Concurrent therapy with: Bepridil; cisapride; ergot derivatives (dihydroergotamine,
             ergonovine, ergotamine, methylergonovine); indinavir; irinotecan; lovastatin;
             midazolam; pimozide; proton pump inhibitors (esomeprazole, lansoprazole, omeprazole);
             rifampin; simvastatin; St John's wort; or triazolam

          8. New or serious opportunistic infection in the past 3 months

          9. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K Grinspoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2006</study_first_submitted>
  <study_first_submitted_qc>December 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2006</study_first_posted>
  <results_first_submitted>November 4, 2009</results_first_submitted>
  <results_first_submitted_qc>January 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2010</results_first_posted>
  <last_update_submitted>March 5, 2010</last_update_submitted>
  <last_update_submitted_qc>March 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>Steven K. Grinspoon, MD</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Kaletra</keyword>
  <keyword>Reyataz</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Lipids</keyword>
  <keyword>Body Composition</keyword>
  <keyword>Receiving Kaletra</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited through information given to HIV-care providers, postings in HIV-community organizations, newspaper advertisements, and the Massachusetts General Hospital research patient data registry. Recruitment began in March, 2006, and continued through May, 2008.</recruitment_details>
      <pre_assignment_details>After screening visit to determine eligibility, subjects were asked to continue their current antiretroviral medications until the baseline visit, immediately after which they were randomized to continue lopinavir/ritonavir or switch to atazanavir/ritonavir.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Boosted Reyataz (ATV/r)</title>
          <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
        </group>
        <group group_id="P2">
          <title>Continue Kaletra (LPV/r)</title>
          <description>Kaletra (pre-study dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Boosted Reyataz (ATV/r)</title>
          <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
        </group>
        <group group_id="B2">
          <title>Continue Kaletra (LPV/r)</title>
          <description>Kaletra (pre-study dose)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="8"/>
                    <measurement group_id="B2" value="50" spread="6"/>
                    <measurement group_id="B3" value="48" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose Trafficking</title>
        <description>6 month mean and standard deviation for glucose uptake into anterior thigh muscle as measured by FDG/PET scanning during euglycemic hyperinsulinemic clamp. During the hyperinsulinemic conditions of the clamp, glucose and 18-FDG [labeled glucose] are taken up by muscle. The quantity of 18-FDG taken up is measured by the PET scan. Although there are no well-accepted norms for this measurement, a higher value indicates that more glucose is being taken up by (or &quot;trafficked to&quot;) muscle. Increased uptake of glucose indicates increased muscle insulin sensitivity.</description>
        <time_frame>6 months</time_frame>
        <population>Only data from subjects with 0 and 6 month Positron Emission Tomography (PET) scans were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Reyataz (ATV/r)</title>
            <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
          </group>
          <group group_id="O2">
            <title>Continue Kaletra (LPV/r)</title>
            <description>Kaletra (pre-study dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Trafficking</title>
          <description>6 month mean and standard deviation for glucose uptake into anterior thigh muscle as measured by FDG/PET scanning during euglycemic hyperinsulinemic clamp. During the hyperinsulinemic conditions of the clamp, glucose and 18-FDG [labeled glucose] are taken up by muscle. The quantity of 18-FDG taken up is measured by the PET scan. Although there are no well-accepted norms for this measurement, a higher value indicates that more glucose is being taken up by (or &quot;trafficked to&quot;) muscle. Increased uptake of glucose indicates increased muscle insulin sensitivity.</description>
          <population>Only data from subjects with 0 and 6 month Positron Emission Tomography (PET) scans were analyzed.</population>
          <units>umol/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7" spread="8.1"/>
                    <measurement group_id="O2" value="24.4" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Initial samples size of N=16 calculated to provide 80% power to detect a 30% change in muscle glucose uptake between groups. Student's t-test used to compare change from baseline and determine treatment effect (net difference over time between the ATV/r vs. LPV/r groups).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>6 month mean and standard deviation for insulin-stimulated glucose uptake (M) per unit insulin at 120 minutes as measured by euglycemic hyperinsulinemic clamp.</description>
        <time_frame>6 months</time_frame>
        <population>Repeated measures analysis using all available data points for each participant</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Reyataz (ATV/r)</title>
            <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
          </group>
          <group group_id="O2">
            <title>Continue Kaletra (LPV/r)</title>
            <description>Kaletra (pre-study dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>6 month mean and standard deviation for insulin-stimulated glucose uptake (M) per unit insulin at 120 minutes as measured by euglycemic hyperinsulinemic clamp.</description>
          <population>Repeated measures analysis using all available data points for each participant</population>
          <units>umol/kg/min per uU/mL insulin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" spread="17.7"/>
                    <measurement group_id="O2" value="49.2" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANCOVA, controlling for baseline values, used to assess treatment effect of the randomization over 6 months (net difference over time between ATV/r vs. LPV/r)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.12</p_value>
            <method>Repeated measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Glucose</title>
        <description>6 month mean and standard deviation for fasting glucose.</description>
        <time_frame>6 months</time_frame>
        <population>Repeated measures analysis using all available data points for each participant</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Reyataz (ATV/r)</title>
            <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
          </group>
          <group group_id="O2">
            <title>Continue Kaletra (LPV/r)</title>
            <description>Kaletra (pre-study dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Glucose</title>
          <description>6 month mean and standard deviation for fasting glucose.</description>
          <population>Repeated measures analysis using all available data points for each participant</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="7"/>
                    <measurement group_id="O2" value="90" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANCOVA, controlling for baseline values, used to assess treatment effect of the randomization over 6 months (net difference over time between ATV/r vs.LPV/r).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Repeated Measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Metabolism - Serum Triglyceride</title>
        <description>6 month mean and standard deviation for serum triglyceride.</description>
        <time_frame>6 months</time_frame>
        <population>Repeated measures analysis using all available data points for each participant</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Reyataz (ATV/r)</title>
            <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
          </group>
          <group group_id="O2">
            <title>Continue Kaletra (LPV/r)</title>
            <description>Kaletra (pre-study dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Metabolism - Serum Triglyceride</title>
          <description>6 month mean and standard deviation for serum triglyceride.</description>
          <population>Repeated measures analysis using all available data points for each participant</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" spread="92"/>
                    <measurement group_id="O2" value="209" spread="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANCOVA, controlling for baseline values, used to assess treatment effect of the randomization over 6 months (net difference over time between ATV/r vs.LPV/r).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Repeated measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition - Visceral Adipose Tissue</title>
        <description>6 month mean and standard deviation for visceral adipose tissue (VAT) as measured by single slice computed tomography (CT) scan at the L4 pedicle (pedicle of 4th lumbar vertebra).</description>
        <time_frame>6 months</time_frame>
        <population>Data from participants with 0 &amp; 6 month data analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Reyataz (ATV/r)</title>
            <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
          </group>
          <group group_id="O2">
            <title>Continue Kaletra (LPV/r)</title>
            <description>Kaletra (pre-study dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition - Visceral Adipose Tissue</title>
          <description>6 month mean and standard deviation for visceral adipose tissue (VAT) as measured by single slice computed tomography (CT) scan at the L4 pedicle (pedicle of 4th lumbar vertebra).</description>
          <population>Data from participants with 0 &amp; 6 month data analyzed.</population>
          <units>square centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="34"/>
                    <measurement group_id="O2" value="167" spread="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Parameters -- CD4 Count</title>
        <description>6 month mean and standard deviation for CD4+ count.</description>
        <time_frame>6 months</time_frame>
        <population>Repeated measures analysis using all available data points for each participant</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Reyataz (ATV/r)</title>
            <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
          </group>
          <group group_id="O2">
            <title>Continue Kaletra (LPV/r)</title>
            <description>Kaletra (pre-study dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Parameters -- CD4 Count</title>
          <description>6 month mean and standard deviation for CD4+ count.</description>
          <population>Repeated measures analysis using all available data points for each participant</population>
          <units>cells/microL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432" spread="192"/>
                    <measurement group_id="O2" value="688" spread="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANCOVA, controlling for baseline values, used to assess treatment effect of the randomization over 6 months (net difference over time between ATV/r vs.LPV/r).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <method>Repeated Measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Enzymes -- Aspartate Aminotransferase (AST)</title>
        <description>6 month mean and standard deviation for AST.</description>
        <time_frame>6 months</time_frame>
        <population>Repeated measures analysis using all available data points for each participant</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Reyataz (ATV/r)</title>
            <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
          </group>
          <group group_id="O2">
            <title>Continue Kaletra (LPV/r)</title>
            <description>Kaletra (pre-study dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Enzymes -- Aspartate Aminotransferase (AST)</title>
          <description>6 month mean and standard deviation for AST.</description>
          <population>Repeated measures analysis using all available data points for each participant</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="29"/>
                    <measurement group_id="O2" value="42" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANCOVA, controlling for baseline values, used to assess treatment effect of the randomization over 6 months (net difference over time between ATV/r vs.LPV/r).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Repeated Measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Enzymes -- Alanine Aminotransferase (ALT)</title>
        <description>6 month mean and standard deviation for ALT.</description>
        <time_frame>6 months</time_frame>
        <population>Repeated measures analysis using all available data points for each participant</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Reyataz (ATV/r)</title>
            <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
          </group>
          <group group_id="O2">
            <title>Continue Kaletra (LPV/r)</title>
            <description>Kaletra (pre-study dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Enzymes -- Alanine Aminotransferase (ALT)</title>
          <description>6 month mean and standard deviation for ALT.</description>
          <population>Repeated measures analysis using all available data points for each participant</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" spread="29"/>
                    <measurement group_id="O2" value="65" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANCOVA, controlling for baseline values, used to assess treatment effect of the randomization over 6 months (net difference over time between ATV/r vs.LPV/r).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Repeated Measures Ancova</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Bilirubin</title>
        <description>6 month mean and standard deviation for total bilirubin.</description>
        <time_frame>6 months</time_frame>
        <population>Repeated measures analysis using all available data points for each participant</population>
        <group_list>
          <group group_id="O1">
            <title>Boosted Reyataz (ATV/r)</title>
            <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
          </group>
          <group group_id="O2">
            <title>Continue Kaletra (LPV/r)</title>
            <description>Kaletra (pre-study dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin</title>
          <description>6 month mean and standard deviation for total bilirubin.</description>
          <population>Repeated measures analysis using all available data points for each participant</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.7"/>
                    <measurement group_id="O2" value="0.6" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated measures ANCOVA, controlling for baseline values, used to assess treatment effect of the randomization over 6 months (net difference over time between ATV/r vs.LPV/r).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Repeated Measures ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 month study period</time_frame>
      <desc>All subjects had physical examinations and were queried about any adverse event at each study visit (baseline, 2 weeks, 1 month, 2 months, 4 months, and 6 months), and bilirubin, ALT, ALT, CD4+ count, and HIV ultrasensitive viral load were sent at all of these timepoints.</desc>
      <group_list>
        <group group_id="E1">
          <title>Boosted Reyataz (ATV/r)</title>
          <description>Boosted Reyataz (300mg atazanavir + 100mg ritonavir)</description>
        </group>
        <group group_id="E2">
          <title>Continue Kaletra (LPV/r)</title>
          <description>Kaletra (pre-study dose)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Giardia Lamblia Infection</sub_title>
                <description>hospitalization required for Giardia lamblia infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <description>Mental status changes requiring hospitalization, found to be caused by combination of prescribed opiates</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>transaminitis</sub_title>
                <description>ALT and/or AST elevated to any degree above the upper limit of normal.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HIV RNA Copy Number Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven K. Grinspoon, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-9109</phone>
      <email>sgrinspoon@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

